Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 5/20 | 0.47 |
| ▸ | GABBR1 | Q9UBS5 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TYR | P14679 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23750203 | 1.00 | GABBR2 (0.47) | GABBR2GABBR1CYP3A4HDAC4HDAC8 | |
| SCHEMBL23750382 | 0.86 | GABBR2 (0.46) | GABBR2GABBR1CYP3A4GAALMNA | |
| SCHEMBL23750223 | 0.86 | GABBR2 (0.46) | GABBR2GABBR1CYP3A4GAALMNA | |
| SCHEMBL23750204 | 0.86 | GABBR2 (0.49) | GABBR2GABBR1CYP3A4HDAC4HDAC8 | |
| SCHEMBL23750126 | 0.86 | GABBR2 (0.49) | GABBR2GABBR1CYP3A4HDAC4HDAC8 | |
| SCHEMBL23750164 | 0.85 | HPGD (0.46) | GABBR2GABBR1CYP3A4ALDH1A1HPGD | |
| SCHEMBL23750200 | 0.85 | HPGD (0.46) | GABBR2GABBR1CYP3A4ALDH1A1HPGD | |
| SCHEMBL24878666 | 0.85 | GABBR2 (0.45) | GABBR2GABBR1CYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL23750211 | 0.85 | GABBR2 (0.45) | GABBR2GABBR1CYP3A4ALDH1A1SMN1; SMN2 | |
| SCHEMBL23750262 | 0.84 | GABBR2 (0.51) | GABBR2GABBR1GAARXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012121-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. | 2023-01-12 | — | — | US | disclosed |
| US-20210246169-A1 | COMPOUNDS | SPERO THERAPEUTICS, INC. (US) | 2021-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012121-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPL21 | GABBR2 4122/4885GABBR1 4101/4885CYP3A4 1369/4885 |
| US-20210246169-A1 | COMPOUNDS | MRPS18A, MRPL37, MRPS35 | GABBR2 4179/4885GABBR1 4092/4885CYP3A4 1405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.